2022 (v1)
Publication
No description
Uploaded on: February 14, 2024
G
F
GUOLO , Fabio
Last name: GUOLO
First name: Fabio
Email: fabio.guolo@unige.it
Institution: UNIGE
Links
-
-
2023 (v1)Publication
No description
Uploaded on: October 25, 2024 -
2019 (v1)Publication
In the last years, natural killer (NK) cell-based immunotherapy has emerged as a promising therapeutic approach for solid tumors and hematological malignancies. NK cells are innate lymphocytes with an array of functional competences, including anti-cancer, anti-viral, and anti-graft-vs.-host disease potential. The intriguing idea of harnessing...
Uploaded on: April 14, 2023 -
2018 (v1)Publication
We report our experience with the use of (1,3)-ß-d-glucan (BDG) screening for the diagnosis of invasive aspergillosis (IA) in neutropenic patients with haematological malignancies. The performance of BDG screening was assessed retrospectively in per patient and per sample analyses. Overall, 20 among 167 patients developed IA (12%). In the per...
Uploaded on: March 27, 2023 -
2015 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2018 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2019 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2018 (v1)Publication
No description
Uploaded on: May 12, 2023 -
2019 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction-consolidation program between 2004 and 2013 were retrospectively analyzed. Median age was 47 years. The first induction course included fludarabine (Flu) and high-dose cytarabine (Ara-C) plus idarubicin (Ida), with or without gemtuzumab-ozogamicin (GO) 3...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were...
Uploaded on: February 4, 2024 -
2017 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2024 (v1)Publication
No description
Uploaded on: October 26, 2024 -
2018 (v1)Publication
Genomic instability plays a pathological role in various malignancies, including acute myeloid leukemia, and thus represents potential therapeutic target. Recent studies demonstrate that SIRT6, a NAD+-dependent nuclear deacetylase, functions as genome-guardian by preserving DNA integrity in different tumor cells. Here, we demonstrate that also...
Uploaded on: March 27, 2023 -
2019 (v1)Publication
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for treatment of various blood cancers. Here, we characterize a new multiple...
Uploaded on: April 14, 2023